Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Fresenius signs sublicense agreement with Luitpold for Venofer in end-stage renal disease

July 10, 2008

Recent Bristol-Myers Squibb patent discloses new agents for cardiovascular disorders

July 10, 2008

Samaritan files IND for SP-6310 in HIV patients with abnormal cortisol levels

July 10, 2008

Affymax completes enrollment in phase III PEARL 1 clinical trial of Hematide

July 10, 2008

Polyphor completes phase I POL-6326 trial in hematopoietic stem cell transplantation

July 10, 2008

2-Methoxyestradiol a potential marker of and treatment for pre-eclampsia

July 10, 2008

Registry data reveal safety, efficacy of Increlex in children with IGF-1 deficiency

July 10, 2008

TIPO-4 extension study confirms tesofensine's efficacy in weight management

July 9, 2008

Recent patents describe new treatment options for endocrine-related disorders

July 9, 2008

LGD-2941 well tolerated, orally bioavailable in healthy subjects

July 9, 2008

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 18, 2026.
ASGCT 2026: Directed evolution in gene therapy
BioWorld
Directed evolution has become a central pillar in gene therapy. This engineering strategy enables the generation of more efficient variants of genetic editors and...
ASGCT 2026: Uncovering the mechanisms of AAV toxicity
BioWorld
Gene therapies rely on vectors to reach the target tissue where they act, such as adeno-associated viruses (AAVs) or lipid nanoparticles (LNPs), among other...
Fosun secures rights to Aribio’s AR-1001 in potential $4.7B deal
BioWorld
Shanghai Fosun Pharmaceutical (Group) Co. Ltd. is paying $60 million up front for an option to secure exclusive rights to Aribio Co. Ltd.’s oral phase III-stage...
Biogen AD drug shows tau, cognition benefit, despite trial miss
BioWorld
Biogen Inc. has decided to advance diranersen (BIIB-080) into registrational trials for early Alzheimer’s disease, even though the antisense oligonucleotide...